Primary Testicular Diffuse Large B-Cell Lymphoma Exhibits Molecular Heterogeneity with Prognostic Biomarkers

Strategic Insights -

Investigations into primary testicular (PT) diffuse large B-cell lymphoma (DLBCL) have revealed a rare and aggressive lymphoma with distinct clinical and molecular characteristics. A study involving 206 patients analyzed DNA and RNA samples using next-generation sequencing platforms and assays to identify prognostic biomarkers. The research was supported by the U.S. Department of Health & Human Services, the National Cancer Institute, Duke University Institutional Research Grant Award, and the Hagemeister Lymphoma Foundation.

Key Takeaways:

  • The study found that PT-DLBCL exhibits molecular heterogeneity in genetic abnormalities and expression profiles of coding genes and microRNAs.
  • Multiple chromosomal copy number variations (CNVs), TP53 transcript mutations with high variant allele frequency, and MCD subtype had significantly adverse prognostic effects.
  • Elevated microsatellite instability had a significantly favorable prognostic effect in PT-DLBCL.
  • Targeted RNA-seq analysis identified a PTL gene expression signature by comparing PT-DLBCL with systemic DLBCL.
  • The study revealed a significant association between the PTL subtype and poorer patient survival, higher frequencies of MYD88 mutations, multiple CNVs, MCD subtype, bulk tumors, and elderly patients in the PT-DLBCL cohort.
  • The ME subtype, on the other hand, featured upregulation of various signaling pathway genes involving the tumor microenvironment and downregulation of BTK and B-cell receptor signaling genes, and was associated with a significantly better clinical outcome than the TLT subtype of PT-DLBCL.
  • Genomic microRNA profiling analysis identified a PTL microRNA signature significantly differentially expressed between PT-DLBCL and systemic DLBCL patients and within the PT-DLBCL cohort.
  • PT-DLBCL patients with higher expression of 16 PTL microRNAs (14 are testicular tissue-specific) had significantly better survival.

Statistics:

  • 206 patients were involved in the study.
  • The study analyzed DNA and RNA samples using next-generation sequencing platforms and assays.
  • 14 testicular tissue-specific microRNAs were identified with a significant association with better survival in PT-DLBCL patients.
  • 16 PTL microRNAs were found to be differentially expressed between PT-DLBCL and systemic DLBCL patients, and within the PT-DLBCL cohort.

Sources:

  • NewsRx LLC. Researchers from Duke University Medical Center Discuss Findings in B-Cell Lymphoma (Prognostic Gene Expression and Microrna Profiling Signatures and Genetic Alterations In Primary Testicular Diffuse Large B-cell Lymphoma). Health & Medicine Week. August 15, 2025; p 6378.
  • Prognostic Gene Expression and Microrna Profiling Signatures and Genetic Alterations In Primary Testicular Diffuse Large B-cell Lymphoma. Blood Cancer Journal, 2025;15(1).